FDA Approval: ANZUPGO (DELGOCITINIB) — Type 1 - New Molecular Entity
FDA-NDA219155 · Dermatology
Topical JAK inhibitor cream billed under Part D pharmacy benefit.
View alertCode intelligence
J9312 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance referencing code J9312.
No alerts currently reference J9312 directly
CMS, MAC, and Federal Register sources are monitored daily. When a policy change references this code, it will appear here automatically.
Latest reimbursement alerts
The most recent policy changes across all codes and specialties.
Low
FDA Approval: LEQSELVI (DEURUXOLITINIB PHOSPHATE) — Type 1 - New Molecular Entity
FDA-NDA217900 · Dermatology
Oral Leqselvi routes to Part D; no J-code applies.
View alertFDA Approval: ONAPGO (APOMORPHINE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer
FDA-NDA214056 · Neurology
New subcutaneous apomorphine solution bills Part B; no J-code yet.
View alertMedicare Coverage Database - New Items
AUTO-1783511452147 · General
This page represents a failed load of the CMS Medicare Coverage Database 'New It
View alertCMS Physician Fee Schedule
AUTO-1783511445304 · Physician Fee Schedule
This page represents the CMS Physician Fee Schedule landing page, which serves a
View alertCMS MAC Archives
AUTO-1783511438006 · General
This source URL points to the CMS MAC Archives page, which is a general navigati
View alertFederal Register Notice: Medicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 24, 2026
FR-2026-13793 · Hospital Outpatient (OPPS)
CMS schedules Aug 24 APC Advisory Panel meeting—OPPS impact ahead.
View alertMedicare Coverage Database - New Items
AUTO-1783427474826 · General
This source URL returned a 404 Page Not Found error from the CMS Medicare Covera
View alert